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Abstract
Background: Depressive disorders are highly prevalent in primary care (PC) and are associated with considerable
functional impairment and increased health care use. Research has shown that many patients prefer psychological
treatments to pharmacotherapy, however, it remains unclear which treatment is most optimal for depressive
patients in primary care.
Methods/Design: A randomized, multi-centre trial involving two intervention groups: one receiving brief cognitive
behavioral therapy and the other receiving general practitioner care. General practitioners from 109 General
Practices in Nijmegen and Amsterdam (The Netherlands) will be asked to include patients aged between 18-70
years presenting with depressive symptomatology, who do not receive an active treatment for their depressive
complaints. Patients will be telephonically assessed with the Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I) to ascertain study eligibility. Eligible patients will be randomized to one of two treatment
conditions: either 8 sessions of cognitive behavioral therapy by a first line psychologist or general practitioner’s
care according to The Dutch College of General Practitioners Practice Guideline (NHG- standaard). Baseline and
follow-up assessments are scheduled at 0, 6, 12 and 52 weeks following the start of the intervention. Primary
outcome will be measured with the Hamilton Depression Rating Scale-17 (HDRS-17) and the Patient Health
Questionnaire-9 (PHQ-9). Outcomes will be analyzed on an intention to treat basis.
Trial Registration: ISRCTN65811640.
Background
Depressive disorders are highly prevalent in primary
care (PC) [1,2] and are associated with considerable
impairment in quality of life [3,4], high service utiliza-
tion use and high medical costs [5]. Most patients with
depressive disorders are seen and treated by their gen-
eral practitioner (GP) [6,7].
The Dutch multidisciplinary guideline (2005) for
Major Depressive Disorder (MDD) and the Dutch Col-
lege of General Practitioners Practice Guideline offer
evidence based treatments for PC patients. Two options
are available: brief psychotherapy and a minimal inter-
vention by the GP, which may include prescribing of
antidepressants. The latter will be referred to as general
practitioners care (GPC).
Prescribing of antidepressants is dependent of suffer-
ing, dysfunction and the preference of patients. However,
research has shown that nowadays many patients prefer
psychological treatments to pharmacotherapy [8,9].
Effective psychological treatments, like brief cognitive
behavioural therapy (bCBT), for depression are available
in PC [10]. However, little is known about the relative
effectiveness of a bCBT compared to GPC. This is most
likely due to limitations in carrying out bCBT studies in
PC. These limitations include for example specialized
and standardized training of primary care professionals
in the intervention.
In the Netherlands, all inhabitants are enlisted with a
GP and have an open and unlimited access to the GP.
The GP performs a gatekeeper function which enables
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him to control access to specialist health care. First line
psychologists (FLP) are operating in PC and are often
connected to the practices of the GP. They offer general-
ized psychological care, mostly after referral of a GP, and
are easily accessible.
The few studies that are available concerning the ben-
efits of bCBT relative to GPC for treating depression in
primary care show conflicting results.
Proutfoot et al, Schoenbaum et al and Simon et al
showed benefits of bCBT relative to GPC [11-13], while
there is also some evidence showing that bCBT might
not be superior to GPC at post treatment [14] and at
12-month follow-up [15].
Methods/Design
Objective
The aim of this paper is to present the research protocol of
our randomized trial designed to compare a protocolized
brief CBT (bCBT) performed by a FLP with a treatment
performed by a general practitioner (general practitioners
care; GPC) for primary care patients with MDD. We
hypothesize that bCBT will be superior to GPC.
Design and setting
Primary care patients with MDD will be randomized to
either an eight session bCBT or GPC of 12 weeks
duration.
The study will be conducted in 109 General Practices
in two regions connected to academic settings in The
Netherlands: the Academic Medical Center in Amster-
dam and the Radboud University Nijmegen Medical
Center in Nijmegen.
Inclusion criteria
Patients aged between 18 and 70 years and suffering
from MDD as determined by an independent researcher
with the Structured Clinical Interview for DSM-IV Axis
I Disorders (SCID-I) [16,17].
Exclusion criteria
- Suffering from schizophrenia or bipolar disorder (now
and in the past as assessed by the SCID-I).
- Contra-indication for MDD treatment like mental
retardation or terminal illness.
- Insufficient comprehension of the Dutch or English
language.
- Severe suicidal thoughts.
- Receiving an active MDD treatment. Active treat-
ment is defined as:
- Antidepressive medication (except those who
receive this in low dosage for pain complaints or as
an anti-smoking intervention: Amitriptyline ≤ 50 mg,
Nortriptyline ≤ 50 mg, Zyban (bupropion)).
- Psychotherapy.
- Supportive consultations by the GP or social
worker, except for diagnostic visits to complete the
diagnosis (≤ 2).
Recruitment of patients and baseline assessment
GPs will be asked to include patients whom they con-
sider to be suffering from MDD. Patients identified by
their GP as suffering from MDD will receive informa-
tion regarding the study and are asked to fill out the
Patient Health Questionnaire (PHQ) [18]. Within 3 days
after inclusion by the GP, a researcher will contact the
patient by telephone to provide further explanation and
seek informed consent regarding the diagnostic phase of
the study. Consenting patients will be further assessed
with a telephonic SCID-I interview. If the patient fulfills
the DSM-IV criteria for MDD, subsequent SCID-I sec-
tions will be checked to assess eligibility. When eligible,
the patient will be further assessed with a baseline
Hamilton Depression Rating Scale-17 (HDRS-17) [19] to
establish the severity of the depression. At the end of
the telephonic assessment the patient receives the
results of the interview and is asked to discuss these
results and the treatment options with the GP. All
results will also be sent to the GP. During the appoint-
ment with the GP the patient will make the decision to
enter the trial or not. If the patient agrees to participate
in the study, a second informed consent form will be
signed and the GP proceeds with the randomisation
procedure as described below.
Randomization
After informed consent, GPs will perform an internet
based randomization procedure. A computer program
generates a stratified block randomization (block rando-
mization of 4 blocks stratified by gender and location
(Nijmegen/Amsterdam)) where the patient is rando-
mized over the two treatment strategies with no prefer-
ence option. The computer then generates an outcome
on the GP’s computer screen and simultaneously sends
an email of this outcome to the researcher. If the patient
is randomized to GPC, the GP will immediately make
the first appointment. If the patient is randomized to
bCBT the researcher will contact the nearest participat-
ing FLP and refer the patient.
Interventions
General Practitioners Care
The treatment protocol is set up in accordance with the
Dutch College of General Practitioners Practice Guide-
line (NHG- standaard) [20] and composed after evaluat-
ing the content of colleague general practitioners’
(follow up) appointments with depressive patients.
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The description of the content of the contacts is
meant as a guideline; GP’s can adapt the scheme to
their own style or to special circumstances. The treat-
ment consists of supportive contacts which can be com-
bined with an antidepressant agent. The duration of the
treatment is 12 weeks. The following elements are
recommended: psycho-education about depression, life
style advices about sleep, alcohol/drugs, nutrition, social
activities and physical activities.
The minimum frequency is one contact every two weeks
during the first six weeks and one telephonic contact and
one face- to- face evaluation contact during the second 6
week period. This can be increased if needed. Reasons for
more contacts can be for instance: the severity of the com-
plaints and/or lack of social support. After the first six
weeks the GP evaluates, together with the patient, the
need and frequency for further contacts. If recovery is not
sufficient, according to the patient and/or GP, the GP will
offer further contacts, during which problem solving
will be a key element. If recovery is substantial the GP will
provide information on relapse prevention and will offer
contacts by telephone during the next month and one
face-to- face contact after six weeks.
See table 1 for an overview of the contents of the GPC.
To monitor the actual content of the provided GPC
and potential supplementary treatment, we will sent
each GP a short questionnaire at the end of the 12
weeks in which they can state how many appointments
they have had with the patient, whether they prescribed
an antidepressant (and the dosage) and whether they
combined their treatment with a treatment by another
health care professional or referred their patient.
In case of randomisation to the FLP, GPs will be
asked to fill in a short questionnaire at the end of the
bCBT in which they can state whether they combined
the bCBT with an antidepressant (and the dosage) and
whether they combined the bCBT treatment with a
treatment by another health care professional or
referred the patient.
Training
In order to optimise the treatment we will pay each par-
ticipating GP a visit before the start of the study. During
this visit we will explain the treatment protocol, content
of the contacts and provide a ring binder with the pro-
tocol. They will also be informed about the possibility of
consulting an independent physician for questions dur-
ing the intervention period.
GPs will be instructed to make a call to the researcher
if they want to divert from the protocol (for example
referring a patient to secondary care or a social worker).
Brief Cognitive Behavioural Therapy (bCBT)
The treatment will consist of 8 sessions within 12
weeks, each of fifty minutes duration. At the end of
each session patients will receive homework assign-
ments. The treatment will be directed at the role of
behaviour and thinking in depressive complaints. Beha-
viour: patients will obtain insight in the role of pleasant
activities on mood and subsequently learn to identify
and expand potentially pleasant activities. Thinking:
patients will obtain insight in the influence of negative
thoughts and beliefs on their feelings/mood and subse-
quently learn to challenge these thoughts and beliefs
thereby reducing the impact on their feelings. The
patient learns to formulate alternative (rational)
thoughts and beliefs. Eventually, the therapy will result
in a personal prevention plan.
All therapists are licensed first line psychologists
trained in this form of cognitive behavioural therapy. To
guarantee quality, the sessions will be audio taped and
the integrity of the intervention will be assessed. Also,
the therapists will perform the intervention under super-
vision, which means that the therapists will regularly
discuss the sessions with colleagues.
See table 2 for an overview of the contents of the bCBT.
Training
The FLPs will be trained in the treatment protocol by
an experienced cognitive behavioural therapist during a
two day course. After this course a booster session is
planned (by then all therapist have performed at least
one 8- session treatment) where problems and questions
encountered during the treatment will be addressed.
Assessments
Patients will be assessed on four occasions: at study entry
(t0), 6 weeks after the start of the intervention (t1), at the
end of the intervention period (i.e. 12 weeks after the
start of the intervention (t2)) and at 52 weeks after the
start of the intervention (follow-up assessment;t3).
Assessments will be performed by experienced
research interviewers who are blind for the type of treat-
ment given. If a patient drops out of treatment an exit
Table 1 Overview of the contents of the GPC
Session nr. Required elements
Contact 1 Discuss the diagnosis, feelings of the patient and psycho-
education (with or without an antidepressant agent)
Contact 2 Evaluation, further psycho-education and life style advices.
Contact 3 Evaluation, re-enforcement and follow-up appointments.
Thereafter if recovery is:
Contact 4+5 Sufficient: contact by telephone to discuss the course and
evaluate possible relapse.
Insufficient: evaluation, reinforcement and problem solving
Contact 6 Sufficient: evaluation, relapse prevention
Insufficient: evaluation, relapse prevention/offer
pharmacological treatment
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assessment with the outcome measure (see paragraph
primary outcome measures) will be completed if possi-
ble. The following socio- demographic data will be col-
lected: sex, age, ethnicity, marital status, education,
primary role and living situation.
Eligibility assessment
The Structured Clinical Interview for DSM-IV Axis I
disorders (SCID-I) is a semi-structured interview
designed for diagnosing mental disorders according to
DSM-IV criteria. Agreement between diagnoses based
on telephone and face to face administration of the
SCID-I is good (Kappa = 0.73 (with 90% agreement)
[21]. The SCID-I will be administered by researchers
that have received a SCID-I training from a professional
that received an official SCID training. Throughout the
study all interviewers will participate in ongoing training
sessions and in monthly consensus meetings to maxi-
mize accuracy and consistency in the administration of
the SCID-I.
Primary outcome measures
Primary outcomes will be depressive symptomatology as
measured by the patient rated PHQ-9 [22], depression
severity as measured by the clinician rated HDRS-17
[19], the proportion of patients achieving response on the
HDRS-17 and the proportion of patients achieving remis-
sion on the HDRS-17. In accordance with the National
Institute of Mental Health criteria [23], response is
defined as a ≥ 50% decrease of the baseline HDRS-17
score, remission is defined as a HDRS-17 score ≤7.
Hamilton Depression Rating Scale- 17 (HDRS-17)
The HDRS-17 is a widely used semi- structured clinical
interview covering a range of affective, behavioral and
biological symptoms and has acceptable psychometric
properties [19]. Throughout the study all HDRS-17
interviewers will participate in ongoing training sessions
and monthly consensus meetings supervised by an
expert psychiatrist to maximize accuracy and consis-
tency in the administration of the HDRS-17.
The Patient Health Questionnaire-9 (PHQ-9)
The PHQ is a relatively short self report version of the
Primary Care Evaluation of Mental Disorders (PRIME-
MD). The full PHQ screens for the five most common
mental disorders using DSM-IV criteria: depressive dis-
orders (MDD and dysthymia), anxiety disorders (panic
disorder and generalized anxiety disorder), alcohol
abuse, somatoform disorder, and eating disorders (buli-
mia nervosa and binge eating disorder) [18]. The PHQ-9
is the 9 item sub-scale for MDD [22].
Secondary outcome measures
The secondary outcome measure is quality of life. It will
be measured with the MOS-SF36, a short-form health
survey consisting of 36 questions. It yields an 8-scale
profile of functional health and well-being as well as a
physical health and mental health summary scale and a
preference-based health utility index. The MOS-SF-36
has been successfully used in surveys of general and spe-
cific populations, to compare the relative burden of dis-
eases, and to assess and compare the health benefits
produced by a wide range of different treatments [24].
Power
Based on Scott et al [25] we expect a medium effect size
(.50) [26] of bCBT as compared to GPC. With an alpha
of 0.05 (one-sided) we will need 51 patients in each
experimental condition to achieve a power of .80 [27].
When taking into account a refusal rate of .20
[25,28-30] we will need 61 patients per treatment condi-
tion, which implies a total sample size of 122 patients.
Data analysis
We will compare the groups at baseline on socio-
demographic characteristics, and functional and clinical
Table 2 Overview of the contents of the bCBT
Session nr. Required elements
Session 1 - Psycho- education
- Explanation of the relation between pleasant activities
and mood
- Explanation of registration activities
- Homework
Session 2 - Review homework assignment
- Identification and expanding of potentially pleasant
activities.
- Explanation of the relation between cognitions and
feelings.
- Explanation 3 columns
- Homework
Session 3 - Review homework assignment
- Explain challenging negative thoughts/formulating
rational thoughts
- Explanation 5 columns
- Homework
Session 4 - Review homework assignment
- Explain challenge tactics again.
- Explanation 7 columns
- Homework
Session 5 - Review homework assignment
- Practice challenging negative thoughts/formulating
rational thoughts
- Optional: explanation of schema’s
- Homework
Session 6 - Review homework assignment
- Explanation and challenging of schema’s
- Homework
Session 7 - Review homework assignment
- Prevention plan
- Homework
Session 8 - Review homework assignment
- How further and prevention plan.
- Evaluation and farewell.
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data to check whether the randomization has been suc-
cessful. The main analyses will be intention to treat.
Treatment effect
To take potential biased outcomes caused by selective
loss to follow-up into account we will use a generalized
linear mixed model (GLMM) analysis approach, which,
assuming missing at random (MAR) for missing values,
gives unbiased effect estimates. MAR is a less restrictive
assumption than missing completely at random and
allows loss to follow-up to be related to baseline charac-
teristics that are incorporated in the regression model. In
all of these analyses intervention is the independent vari-
able and a propensity score is entered as covariate to
adjust for potential confounders. All analyses with
dichotomous outcomes will be carried out with General-
ized Estimating Equations (GEE).
Ethical aspects
The study protocol is approved by the institutional
ethics review committee of both participating centers.
Informed consent will be obtained from the participants
at two moments in the study, namely before entering the
study and before randomization. Prior to giving consent,
the patients will be provided with all the aims and charac-
teristics of the study and the two interventions.
For the patients randomized to the bCBT there will be
another informed consent moment. Namely, before the
start of the therapy informed consent will be obtained
for audio taping the sessions.
Finally, all patients will be informed that participation is
voluntary and that they are able to withdraw at any time.
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